These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35790916)

  • 1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
    Provencio M; Cobo M; Rodriguez-Abreu D; Calvo V; Carcereny E; Cantero A; Bernabé R; Benitez G; Castro RL; Massutí B; Del Barco E; García Campelo R; Guirado M; Camps C; Ortega AL; González Larriba JL; Sánchez A; Casal J; Sala MA; Juan-Vidal O; Bosch-Barrera J; Oramas J; Dómine M; Trigo JM; Blanco R; Calzas J; Morilla I; Padilla A; Pimentao J; Sousa PA; Torrente M
    BMC Cancer; 2022 Jul; 22(1):732. PubMed ID: 35790916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
    Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
    J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP).
    Martín-López J; Rojo F; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; de Alda LR; García JF; Salas C
    J Clin Pathol; 2023 May; 76(5):327-332. PubMed ID: 34903610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
    Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
    Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
    Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
    Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
    Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
    BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
    Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
    Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
    BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
    Steeghs EMP; Groen HJM; Schuuring E; Aarts MJ; Damhuis RAM; Voorham QJM; ; Ligtenberg MJL; Grünberg K
    Lung Cancer; 2022 May; 167():87-97. PubMed ID: 35461050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Enguita AB
    Clin Transl Oncol; 2023 May; 25(5):1252-1267. PubMed ID: 36571695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
    Nadler E; Vasudevan A; Wang Y; Ogale S
    Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Griesinger F; Eberhardt W; Nusch A; Reiser M; Zahn MO; Maintz C; Bernhardt C; Losem C; Stenzinger A; Heukamp LC; Büttner R; Marschner N; Jänicke M; Fleitz A; Spring L; Sahlmann J; Karatas A; Hipper A; Weichert W; Heilmann M; Sadjadian P; Gleiber W; Grah C; Waller CF; Reck M; Rittmeyer A; Christopoulos P; Sebastian M; Thomas M;
    Lung Cancer; 2021 Feb; 152():174-184. PubMed ID: 33358484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.
    Lemmon CA; Zhou J; Hobbs B; Pennell NA
    JCO Precis Oncol; 2023 Jan; 7():e2200294. PubMed ID: 36634300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
    Garrido P; de Castro J; Concha Á; Felip E; Isla D; López-Ríos F; Paz-Ares L; Ramírez J; Sanz J; Gómez JJ
    Clin Transl Oncol; 2012 May; 14(5):338-49. PubMed ID: 22551539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Belén Enguita A
    Rev Esp Patol; 2023; 56(2):97-112. PubMed ID: 37061248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.